ALX ONCOLOGY HLDGS INC's ticker is ALXO and the CUSIP is 00166B105. A total of 101 filers reported holding ALX ONCOLOGY HLDGS INC in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $8,846,491 | -34.1% | 1,843,019 | +3.0% | 0.00% | – |
| Q2 2023 | $13,433,589 | +78.1% | 1,788,760 | +7.2% | 0.00% | – |
| Q1 2023 | $7,542,180 | -60.7% | 1,668,624 | -1.9% | 0.00% | -100.0% |
| Q4 2022 | $19,171,240 | +19.9% | 1,701,086 | +1.8% | 0.00% | 0.0% |
| Q3 2022 | $15,987,000 | +18.9% | 1,670,402 | +0.5% | 0.00% | – |
| Q2 2022 | $13,447,000 | -41.3% | 1,662,282 | +22.6% | 0.00% | -100.0% |
| Q1 2022 | $22,907,000 | -20.5% | 1,355,478 | +1.1% | 0.00% | 0.0% |
| Q4 2021 | $28,811,000 | -71.5% | 1,340,571 | -1.9% | 0.00% | -66.7% |
| Q3 2021 | $100,950,000 | +47.4% | 1,366,761 | +9.1% | 0.00% | +50.0% |
| Q2 2021 | $68,475,000 | -38.8% | 1,252,305 | -17.5% | 0.00% | -33.3% |
| Q1 2021 | $111,973,000 | -5.4% | 1,518,480 | +10.6% | 0.00% | -25.0% |
| Q4 2020 | $118,331,000 | +278.2% | 1,372,749 | +65.6% | 0.00% | +300.0% |
| Q3 2020 | $31,287,000 | – | 829,014 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| venBio Partners LLC | 9,699,925 | $163,929,000 | 36.34% |
| Logos Global Management LP | 3,011,352 | $50,892,000 | 6.60% |
| Vivo Capital, LLC | 4,220,048 | $71,319,000 | 4.91% |
| Samsara BioCapital, LLC | 262,786 | $4,441,000 | 1.12% |
| Cormorant Asset Management, LP | 712,079 | $12,034,000 | 0.92% |
| Pier Capital, LLC | 394,443 | $6,666,000 | 0.85% |
| Redmile Group, LLC | 772,397 | $13,054,000 | 0.41% |
| Artal Group S.A. | 500,000 | $8,450,000 | 0.35% |
| Nan Fung Group Holdings Ltd | 41,950 | $709,000 | 0.34% |
| Orbimed Advisors | 621,700 | $10,507,000 | 0.17% |